AMENDMENTS TO THE CLAIMS

Please amend claims 18-22. The listing of claims below will replace all prior versions and listings of claims in the application. Deletions appear in strikethrough font, and additions are underlined.

Complete listing of claims

Claims 1-11 (Cancelled)

- 12. (Previously Presented) A method for the treatment of depression or an anxiety state in a human in need thereof, comprising administering to said human an effective amount of an inhibitor of the t-PA-mediated activation of a glutamate receptor.
- (Previously Presented) A method according to claim 12, wherein the glutamate receptor is of the NMDA type.
- 14. (Previously Presented) A method according to claim 12, wherein the inhibitor is a protease.
- 15. (Previously Presented) A method according to claim 14, wherein the protease is a serine protease inhibitor.
- 16. (Previously Presented) A method according to claim 15, wherein the serine protease inhibitor is chosen from neuroserpin, plasminogen activator inhibitor (PAI), and protease nexin I (PN-1).

- 17. (Previously Presented) A method according to claim 12, wherein the inhibitor is chosen from DSPA and a DSPA derivative, analog, or fragment.
- 18. (Currently Amended) A method according to claim 17, wherein the sequence of the DSPA or DSPA derivative, analog, or fragment is the amino acid sequence shown in Figure 1 of SEQ ID NO:1 or has at least 70% homology with the sequence-shown in Figure 1 of SEQ ID NO:1.
- 19. (Currently Amended) A method according to claim 18, wherein the sequence of the DSPA or DSPA derivative, analog, or fragment has from 80 to 90% homology with the sequence-shown in Figure 1 of SEQ ID NO:1.
- 20. (Currently Amended) A method according to claim 17, wherein a DSPA having the amino acid sequence shown in Figure 1 is administered to the a human in a dose greater than 62.560 and lower than 160 microgram/kg; erwherein the DSPA has the amino acid sequence of SEQ ID NO:1 wherein a DSPA derivative, analog, or fragment is administered to the human in a dose adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and a DSPA having the amino acid sequence shown in Figure 1.
- 21. (Currently Amended) A method according to claim 17,

wherein a DSPA or a DSPA derivative, analog, or fragment having the amino acid sequence shown in Figure 1-is administered to the a human in a dose from 90 to 125 microgram/kg; erwherein the DSPA has the amino acid sequence of SEQ ID NO:1 wherein a DSPA derivative, analog, or fragment is administered to the human in a dose adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and the DSPA having the amino acid sequence shown in

22. (Currently Amended) A method according to claim 17, wherein a DSPA or a DSPA derivative, analog, or fragment having the amino-acid sequence shown in Figure 1-is administered to the a human in a dose of about 90 microgram/kg; or wherein the DSPA has the amino acid sequence of SEQ ID NO:1wherein a DSPA derivative, analog, or fragment is administered to the human in a dose-adjusted accordingly, based on the bioequivalence of the DSPA derivative, analog, or fragment and the DSPA having the amino acid sequence shown in Figure 1.

Figure 1.

23. (Previously Presented) A method for the treatment of stroke in a human in need thereof comprising administering to said human an effective amount of a DSPA or a DSPA derivative, analog, or fragment and a thrombolytic.

Attorney Docket No. 09498.0017 U.S. Application No.: 10/555,583

- (Previously Presented) A method according to claim 23, wherein the thrombolytic is t-PA.
- 25. (Previously Presented) A method for providing neuroprotection in a human in need thereof comprising administering to said human an effective amount of a DSPA or a DSPA derivative, analog, or fragment.
- 26. (Previously Presented) A method according to claim 25, wherein the method for providing neuroprotection is a method for the treatment or prophylaxis of a condition chosen from Parkinsonism, Alzheimer's, Huntington's chorea, diabetes, painful conditions, epilepsy, and memory disturbances.
- 27. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose greater than 60 and lower than 160 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.
- 28. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose from 90 to 125 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.
- 29. (New) A method according to claim 17, wherein the DSPA derivative, analog, or fragment is administered to a human in a dose bioequivalent to the administration of a dose of about 90 microgram/kg of a DSPA having the amino acid sequence of SEQ ID NO:1.